Supplemental material
Journal of Medical Economics
Volume 26, 2023 - Issue 1
Open access
5,236
Views
0
CrossRef citations to date
0
Altmetric
Oncology
Cost-effectiveness of combination therapy of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone for previously untreated diffuse large B-cell lymphoma in Japan
Takashi Mizuokaa Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, JapanCorrespondence[email protected]
https://orcid.org/0009-0009-1668-9993
, https://orcid.org/0009-0009-1668-9993
Hiroyuki Sakamakib Graduate School of Health Innovation, Kanagawa University of Human Services, Kanagawa, Japan
, Shigeo Fujic Department of Hematology, Osaka International Cancer Institute, Osaka, Japanhttps://orcid.org/0000-0001-5118-7950
, Shota Saitod CRECON Medical Assessment Inc., Tokyo, Japan
, Tatsunori Muratad CRECON Medical Assessment Inc., Tokyo, Japan
, Shinya Ohnoa Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japanhttps://orcid.org/0000-0002-4157-9165
, Naoki Inubashiria Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japanhttps://orcid.org/0009-0005-9179-9800
, Tomoha Oshimaa Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japanhttps://orcid.org/0009-0005-1317-0425
& Kazuhito Yamamotoe Aichi Cancer Center, Aichi, Japanhttps://orcid.org/0000-0002-8588-8955
show all
Pages 1122-1133
|
Received 23 May 2023, Accepted 29 Aug 2023, Published online: 12 Sep 2023
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.